FDA looks at obesity devices for children
This article was originally published in Clinica
Executive Summary
The FDA's paediatric advisory committee, long focused on drug matters, turns to a timely device topic next month - paediatric obesity, clinical trial designs for devices intended to treat obesity in children and related ethical issues. With as many as 15% of children and adolescents (aged 6-19) obese or overweight, and obesity in adolescents rapidly becoming a national epidemic, manufacturers are interested in devices that can treat the problem.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.